Mon, December 19, 2022
Fri, December 16, 2022
Thu, December 15, 2022
Wed, December 14, 2022
Tue, December 13, 2022

Alec Stranahan Maintained (YMAB) at Hold with Increased Target to $6 on, Dec 15th, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. with-increased-target-to-6-on-dec-15th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Alec Stranahan of B of A Securities, Maintained "Y-mAbs Therapeutics, Inc." (YMAB) at Hold with Increased Target from $5 to $6 on, Dec 15th, 2022.

Alec has made no other calls on YMAB in the last 4 months.



There are 6 other peers that have a rating on YMAB. Out of the 6 peers that are also analyzing YMAB, 2 agree with Alec's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Michael Ulz of "Morgan Stanley" Maintained at Hold with Decreased Target to $8 on, Monday, October 31st, 2022
  • David Nierengarten of "Wedbush" Downgraded from Buy to Hold and Held Target at $6 on, Monday, October 31st, 2022


These are the ratings of the 4 analyists that currently disagree with Alec


  • Etzer Darout of "BMO Capital" Maintained at Buy with Decreased Target to $12 on, Tuesday, November 1st, 2022
  • Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $19 on, Monday, October 31st, 2022
  • Tessa Romero of "JP Morgan" Downgraded from Hold to Sell and Decreased Target to $7 on, Monday, October 31st, 2022
  • William Maughan of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $27 on, Monday, October 31st, 2022

Publication Contributing Sources